<DOC>
	<DOCNO>NCT02208037</DOCNO>
	<brief_summary>Acute Graft-versus-Host-Disease ( GVHD ) important cause morbidity mortality allogeneic hematopoietic stem cell transplantation ( HSCT ) . This study aim determine three new GVHD prophylaxis approach improve rate GVHD relapse free survival one year transplant compare current standard prophylaxis regimen .</brief_summary>
	<brief_title>Novel Approaches Graft-versus-Host Disease Prevention Compared Contemporary Controls ( BMT CTN 1203 )</brief_title>
	<detailed_description>GVHD complication occur bone marrow stem cell transplant . The transplant recipient 's body attack newly introduce cell . Only 40 % patient acute GVHD durable response treat corticosteroid therapy . A strategy help few people suffer GVHD , without adverse effect , would effective approach improve survival allogeneic transplantation . GVHD incidence decrease various treatment plan . Early transplant do use post-transplant methotrexate prevent GVHD . Another drug , cyclosporine , later show work well methotrexate . Then doctor discover combined use cyclosporine methotrexate work even well either agent alone . More recently , calcineurin-inhibitors , tacrolimus develop GVHD prophylactic agent due favorable toxicity profile comparison cyclosporine . Studies conduct compare available treatment combination relate unrelated donor . The combination tacrolimus/methotrexate remain standard GVHD prophylaxis . However , improve GVHD prophylaxis remain significant clinical need HSCT . The current clinical trial test three novel GVHD prophylaxis approach : tacrolimus/methotrexate bortezomib ( Tac/MTX/Bort ) , tacrolimus/methotrexate maraviroc ( Tac/MTX/MVC ) tacrolimus/mycophenolate mofetil cyclophosphamide ( Tac/MMF/Cy ) . This randomized Phase II clinical trial compare intervention arm Tac/MTX control . This study enroll people cancer blood lymph glands stem cell transplant treatment option . The study take least two year include 270 participant - 90 participant three treatment group . The purpose study compare three combination medication see whether one good current standard care ( Tacrolimus/Methotrexate ) prevent GVHD .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>1 . Age 1875 year ( patient old 18.0 less 76.0 year old ) 2 . Patients acute leukemia , chronic myelogenous leukemia myelodysplasia circulate blast le 5 % blast bone marrow . 3 . Patients chronic lymphocytic leukemia/small lymphocytic lymphoma , follicular , marginal zone , diffuse large Bcell , Hodgkin 's Lymphoma , mantle cell lymphoma chemosensitive disease time transplantation 4 . Planned reduced intensity condition regimen ( see eligible regimen Table 2.4a ) 5 . Patients must relate unrelated peripheral blood stem cell donor follow : 1 . Sibling donor must 6/6 match HLAA B intermediate ( high ) resolution , DRB1 high resolution use DNAbased typing , must willing donate peripheral blood stem cell meet institutional criterion donation . 2 . Unrelated donor must 7/8 8/8 match HLAA , B , C DRB1 high resolution use DNAbased typing . Unrelated donor must willing donate peripheral blood stem cell medically clear donate stem cell accord National Marrow Donor Program ( NMDP ) criterion . 6 . Cardiac function : Ejection fraction rest ≥ 45 % 7 . Estimated creatinine clearance great 50 mL/minute ( use CockcroftGault formula actual body weight ) 8 . Pulmonary function : Diffusing capacity lung carbon monoxide ( DLCO ) ≥ 40 % ( adjust hemoglobin ) force expiratory volume one second ( FEV1 ) ≥ 50 % 9 . Liver function : total bilirubin &lt; 1.5 x upper limit normal alanine aminotransferase ( ALT ) /aspartate aminotransferase ( AST ) &lt; 2.5x upper normal limit . Patients diagnose Gilbert 's Disease allow exceed define bilirubin value 1.5x upper limit normal . 10 . Female subject ( unless postmenopausal least 1 year screen visit , surgically sterilize ) , agree practice two ( 2 ) effective method contraception time , agree completely abstain heterosexual intercourse , time signing inform consent 12 month post transplant ( see Section 2.6.4 definition postmenopausal ) . 11 . Male subject ( even surgically sterilize ) , partner woman childbearing potential must agree one following : practice effective barrier contraception ( see Section 2.6.4 list barrier method ) , abstain heterosexual intercourse time sign informed consent 12 month post transplant . 12 . Signed informed consent 1 . Prior allogeneic transplant 2 . Karnofsky Performance Score &lt; 70 % 3 . Active central nervous system ( CNS ) involvement malignant cell 4 . Patients uncontrolled bacterial , viral fungal infection ( currently take medication progression clinical improvement ) time enrollment . 5 . Presence fluid collection ( ascites , pleural pericardial effusion ) interfere methotrexate clearance make methotrexate use contraindicate 6 . Patients transform lymphoma ( e.g. , Richters transformation arise follicular lymphoma chronic lymphocytic leukemia ) 7 . Patients seropositive human immunodeficiency virus ( HIV ) 8 . Patient active Hepatitis B C determine serology and/or nucleic acid amplification test ( NAAT ) 9 . Patients hypersensitivity bortezomib , boron mannitol 10 . Patients ≥ grade 2 sensory peripheral neuropathy 11 . Myocardial infarction within 6 month prior enrollment New York Heart Association ( NYHA ) Class III IV heart failure ( see Appendix D ) , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Prior study entry , ECG abnormality screen must document investigator medically relevant . 12 . Female patient lactate pregnant 13 . Patients serious medical psychiatric illness likely interfere participation clinical study 14 . Patients prior malignancy except resect basal cell carcinoma treat cervical carcinoma situ . Cancer treat curative intent ≥ 5 year previously allow . Cancer treat curative intent &lt; 5 year previously allow unless approve Protocol Officer one Protocol Chairs . 15 . Planned use antithymocyte globulin ( ATG ) alemtuzumab condition regimen . 16 . Planned posttransplant therapy , include use tyrosinekinase inhibitor ( TKI ) . 17 . Inability withhold agent may interact hepatic cytochrome P450 enzymes ( CYP3A4 ) , glutathione Stransferases involve bortezomib and/or busulfan metabolism day 5 day +7 . It acceptable use alternative noninteracting medication period , resume prior medication . 18 . Patients secondary acute myeloid leukemia arise myeloproliferative disease , include Chronic myelomonocytic leukemia ( CMML ) , evidence active myeloproliferative feature myelofibrosis background .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Acute Lymphoblastic Leukemia/Lymphoma</keyword>
	<keyword>Acute Myelogenous Leukemia</keyword>
	<keyword>Mantel-Cell Lymphoma</keyword>
	<keyword>Hematopoietic Transplant</keyword>
	<keyword>GVHD Prophylaxis</keyword>
</DOC>